Osaic Holdings
PBE icon

Osaic Holdings’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Osaic Holdings’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
9,641
+827
+9% +$68.1K ﹤0.01% 3153
2026
Q1 		$698K Sell
8,814
-149
-2% -$12K ﹤0.01% 3040
2025
Q4 		$736K Sell
8,963
-452
-5% -$35K ﹤0.01% 2990
2025
Q3 		$646K Sell
9,415
-26
-0.3% -$1.76K ﹤0.01% 3208
2025
Q2 		$605K Buy
9,441
+852
+10% +$52.8K ﹤0.01% 2966
2025
Q1 		$545K Sell
8,589
-519
-6% -$34.9K ﹤0.01% 2781
2024
Q4 		$606K Sell
9,108
-2,974
-25% -$205K ﹤0.01% 2610
2024
Q3 		$844K Buy
12,082
+147
+1% +$10.2K ﹤0.01% 2394
2024
Q2 		$773K Sell
11,935
-3,788
-24% -$240K ﹤0.01% 2401
2024
Q1 		$1.02M Buy
15,723
+279
+2% +$18.2K ﹤0.01% 2308
2023
Q4 		$1.02M Sell
15,444
-6,237
-29% -$363K ﹤0.01% 2493
2023
Q3 		$1.24M Buy
21,681
+4,758
+28% +$290K ﹤0.01% 2438
2023
Q2 		$1.04M Buy
16,923
+715
+4% +$44.6K ﹤0.01% 2491
2023
Q1 		$1.02M Sell
16,208
-95
-0.6% -$6.12K ﹤0.01% 2451
2022
Q4 		$1.03M Buy
16,303
+714
+5% +$45.3K ﹤0.01% 2332
2022
Q3 		$919K Buy
15,589
+323
+2% +$19.9K ﹤0.01% 2314
2022
Q2 		$884K Buy
15,266
+264
+2% +$15.2K ﹤0.01% 2399
2022
Q1 		$861K Sell
15,002
-18,564
-55% -$1.13M ﹤0.01% 2717
2021
Q4 		$2.39M Sell
33,566
-9,034
-21% -$654K ﹤0.01% 1628
2021
Q3 		$3.19M Sell
42,600
-47
-0.1% -$3.58K 0.01% 1361
2021
Q2 		$3.3M Sell
42,647
-3,725
-8% -$277K 0.01% 1324
2021
Q1 		$3.42M Buy
46,372
+2,529
+6% +$191K 0.01% 1193
2020
Q4 		$3.07M Buy
43,843
+3,292
+8% +$208K 0.01% 1147
2020
Q3 		$2.3M Buy
40,551
+59
+0.1% +$3.47K 0.01% 1223
2020
Q2 		$2.36M Sell
40,492
-28,255
-41% -$1.54M 0.01% 1156
2020
Q1 		$3.2M Buy
+68,747
New +$3.59M 0.01% 805

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Osaic Holdings's PBE Position: Q2 2026 in Review

Osaic Holdings increased its Invesco Biotechnology & Genome ETF (PBE) stake by 9.4% in Q2 2026, buying an estimated $68.1K and bringing the position to 9,641 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Osaic Holdings first reported a position in PBE in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.42M in Q1 2021. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • Osaic Holdings held 9,641 shares of Invesco Biotechnology & Genome ETF worth $864K as of Q2 2026.
  • Osaic Holdings bought 827 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $68.1K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #3153 holding.
  • Osaic Holdings first reported a position in Invesco Biotechnology & Genome ETF in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Invesco Biotechnology & Genome ETF position peaked at $3.42M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.